SAN FRANCISCO, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Novotech, a global full-service clinical Contract Research Organization (CRO) focused on partnering with biotech companies to accelerate the development of advanced and novel therapeutics at every phase, announced today that it will have the largest ever presence at the J.P.Morgan Healthcare Conference in San Francisco, CA, USA, January 8-11, 2024.

This marks a significant milestone for the company as it has finalized the integration of its acquisitions of EastHORN and CBR International solidifying its position as a leading global CRO for the biotech sector.

The executive team will be participating in the following partnering platforms during the Conference:

CTIC – January 7, 2024, at the Intercontinental San Francisco
Biotech Showcase – January 8-10, 2024, at the San Francisco Hilton
BIO Partnering – January 8-11, 2024, at the San Francisco Marriott Marquis
RESI – January 9, 2024, at the Marines Memorial Club

Schedule a meeting with the team

Novotech offers an integrated and scaleable clinical development approach across more than 25 geographies and is highly regarded for its scientific expertise in key therapeutic areas including:

Oncology
Cell & Gene Therapy
Liver disease
Infectious diseases and vaccines
Orphan and rare diseases

Novotech has more than 3,000 employees across 34 office locations in the US, Greater China, South Korea, Australia, New Zealand, and Europe.

The CRO offers biotechs a unique and unparalleled suite of early to late-phase services across the US and Europe, with a foundation in Asia Pacific where the company has built a reputation for delivering high-quality expedited clinical trials. Its commitment to collaboration is evident in the 50 Leading Site Partnership agreements it has signed over the past three years.

About Novotech Novotech-CRO.com

Founded in 1997, Novotech is a global full-service clinical Contract Research Organization (CRO) focused on partnering with biotech companies to accelerate the development of advanced and novel therapeutics at every phase.

Recognized for its industry-leading contributions, Novotech has received numerous prestigious awards, including the CRO Leadership Award 2023, the Asia Pacific Cell & Gene Therapy Clinical Trials Excellence 2023, the Asia-Pacific Contract Research Organization Company of the Year Award since 2006.

The Company offers a comprehensive suite of services including laboratories, Phase I facilities, drug development consulting, regulatory expertise, and has experience with over 5,000 clinical projects, including Phase I to Phase IV clinical trials and bioequivalence studies. With a presence in 34 office locations and a dedicated team of 3,000+ professionals worldwide, Novotech is a trusted end-to-end strategic partner of choice.

For more information or to speak to an expert team member visit www.Novotech-CRO.com

This item of content is a press release from a third party provider who make no warranties or representations in connection with this content and therefore PA can make no warranties in respect of its use.

Tags

More Like This

Novotech Honored with Frost & Sullivan’s 2024 Best Practices Company of the Year Award for Leadership in Biotech CRO Services

Novotech Secures Consecutive Frost & Sullivan CRO Company of the Year Award

Novotech Recognized for Excellence in Business Expansion, Innovation, and Marketing at the 2024 Clinical Trials Arena Excellence Awards

Novotech Named a Fierce CRO Award Winner in the Excellence in Clinical Trial Management and Global Operations Categories

Novotech Named Best Contract Research Organization in Australia at Asia-Pacific Biopharma Excellence Awards 2025

Novotech Appoints Commercial and Clinical Life Sciences Specialist to Head Up Global Drug Development Consulting Team

Novotech Awarded Cell & Gene Therapy CRO Excellence 2023

Novotech Publishes Comprehensive Report on the Global Vaccine Clinical Trials Landscape